-
Tolmar Announces Expanded Indication for Rubraca® (rucaparib) First and Only PARP Inhibitor to Outperform Docetaxel in a Head-to-Head Phase 3 Trial
19 Dec 2025 15:09 GMT
… metastatic castration-resistant prostate cancer (mCRPC) patients
… 39;s choice of docetaxel, abiraterone acetate, or … metastatic castration-resistant prostate cancer (mCRPC) who have … . Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment …
-
<![CDATA[FDA Grants Regular Approval to Rubraca for Some With Prostate Cancer]]>
18 Dec 2025 02:53 GMT
… metastatic castration-resistant prostate cancer (mCRPC) that has … previously received, or docetaxel, with the trial … Metastatic Castration-Resistant Prostate Cancer That Expresses a … -prostate-cancer-expresses-brca-gene-mutation
3. Personalizing Prostate Cancer …
-
FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer
18 Dec 2025 00:29 GMT
… somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an … (enzalutamide or abiraterone acetate) or docetaxel. Randomization was stratified by performance …
-
<![CDATA[Sequencing vs upfront intensification in metastatic prostate cancer]]>
17 Dec 2025 19:05 GMT
… management of metastatic castration-sensitive prostate cancer, with particular attention to … disease. Participants described using docetaxel in combination with ADT in … the ongoing evolution of metastatic prostate cancer management. While acknowledging that …
-
<![CDATA[Clinical strategies for treating metastatic castration-sensitive prostate cancer]]>
17 Dec 2025 01:29 GMT
… management of metastatic castration-sensitive prostate cancer (mCSPC). The conversation centered … prominently studied in combination with docetaxel in high-volume disease, clinicians … ADT, an ARPI, and docetaxel. Although acknowledging the survival benefit …
-
Proteome-Wide Mapping of Artesunate Targets Reveals Enrichment of the Ubiquitin-Proteasome System
17 Dec 2025 15:25 GMT
… demonstrated repressing the growth of docetaxel-resistant prostate cancer cells.67 Further mechanisms … inhibits the growth behavior of docetaxel-resistant prostate cancer cells. Front Oncol. 2022 …
-
Why is everyone talking about Telix shares this week?
18 Dec 2025 04:35 GMT
… is testing its lead prostate cancer therapy candidate, TLX591 ( … with metastatic castration resistant prostate cancer (mCRPC). According to … (abiraterone, enzalutamide, or docetaxel) versus the standard of … 1, including the docetaxel cohort which was the …
-
<![CDATA[FDA Approves Rucaparib in BRCA-Mutated mCRPC ]]>
18 Dec 2025 04:16 GMT
… control therapy, consisting of docetaxel or an alternative second- … with enzalutamide, abiraterone acetate, or docetaxel (HR, 0.50; 95% … castration-resistant-prostate-cancer
Scott J. Understanding metastatic castration-resistant prostate cancer. Verywellhealth …
-
<![CDATA[FDA Approves Rucaparib for the Treatment of Adults With mCRPC]]>
18 Dec 2025 03:03 GMT
… -associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with … Zytiga; Janssen Biotech]), or docetaxel. Randomization was stratified by … With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene …
-
<![CDATA[FDA approves rucaparib for chemotherapy-naïve, BRCA-mutated mCRPC ]]>
18 Dec 2025 02:58 GMT
… associated metastatic castration-resistant prostate cancer (mCRPC) who … or abiraterone acetate) or docetaxel. Among all patients, … metastatic castration-resistant prostate cancer. News release. … metastatic-castration-resistant-prostate-cancer
2. FDA grants …
About
© 1995-2025